Efficacy and Safety of Omalizumab in Chinese Pediatric Patients Under 12 with Chronic Urticaria: A Case Series Analysis
-
By
-
Hui Zhao
-
Lei Luo
-
Wan-Ming Jia
-
April 21, 2026
-
0 min
Top Institutions in Pediatrics
Brief introduction explaining scope and methodology.
-
#1
National Institute of Allergy and Infectious Diseases (NIAID), NIH
Bethesda, MD
Key Differentiators
- Pediatric Allergy and Immunology
- Immunology
- Clinical Trials
-
#2
Children's Hospital of Philadelphia (CHOP)
Philadelphia, PA
Key Differentiators
- Pediatric Allergy and Immunology
- Dermatology
-
#3
Johns Hopkins Children's Center
Baltimore, MD
Key Differentiators
- Pediatric Allergy and Immunology
- Clinical Immunology
-
#4
Second Hospital of Hebei Medical University
Shijiazhuang, Hebei
Key Differentiators
- Pediatric Allergy and Immunology
-
#5
Massachusetts General Hospital for Children
Boston, MA
Key Differentiators
- Pediatric Allergy and Immunology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.